← Back to Search

Behavioural Intervention

Pharmacist Intervention for High Cholesterol

N/A
Waitlist Available
Led By Kayla Marvin, PharmD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of coronary artery disease
Be older than 18 years old
Must not have
End-stage liver disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 5
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to see if pharmacists can help improve the use of cholesterol-lowering medications for people who have already had heart problems, compared to the usual care they receive."

Who is the study for?
This trial is for patients with coronary artery disease and high LDL cholesterol levels (>55), who are currently seeing a primary care physician at one of six specific clinics. It excludes women who could become pregnant, those managed by other practices, hospice or long-term care residents, and individuals with end-stage liver disease.
What is being tested?
The study aims to compare the effectiveness of pharmacist-led interventions in managing cholesterol using guideline-directed therapies versus usual care without this specialized intervention for secondary prevention in very high-risk patients.
What are the potential side effects?
Since the intervention involves pharmacists optimizing lipid-lowering therapy as per guidelines rather than testing new medications, side effects would be related to individual responses to existing cholesterol treatments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with coronary artery disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My liver is in its final stage of disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 5
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 5 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Subjects who meet low-density lipoprotein (LDL) at goal (<55)
Secondary study objectives
Number of Medication related problems identified and solved
Number of Medications initiated or titrated
Number of Subjects with Prevalence of elevated Lipoprotein(a)
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Pharmacist InterventionExperimental Treatment1 Intervention
Pharmacist review of patient chart and follow up visits to prescribe appropriate therapy for hyperlipidemia.
Group II: ControlActive Control1 Intervention
Chart review only

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,394 Previous Clinical Trials
2,459,886 Total Patients Enrolled
1 Trials studying High Cholesterol
1,008 Patients Enrolled for High Cholesterol
Kayla Marvin, PharmDPrincipal InvestigatorWake Forest University Health Sciences
~100 spots leftby Mar 2025